30EE+DRSP is developed by University of Sao Paulo.

What development phase is 30EE+DRSP in?

30EE+DRSP is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

30EE+DRSP

University of Sao Paulo · FDA-approved active Small molecule Quality 4/100

30EE+DRSP, developed by the University of Sao Paulo, is a marketed drug with an unknown mechanism of action and a key composition patent expiring in 2028. The drug's primary strength lies in its current market presence, despite the lack of detailed clinical trial results and revenue data. The primary risk is the uncertainty surrounding its mechanism of action, which could impact future regulatory and market acceptance.

At a glance

Generic name	30EE+DRSP
Sponsor	University of Sao Paulo
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Contraceptives Containing Drospirenone and Blood Pressure (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

30EE+DRSP CI brief — competitive landscape report
30EE+DRSP updates RSS · CI watch RSS
University of Sao Paulo portfolio CI